PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPatiromer
Veltassa(patiromer)
Veltassa (patiromer) is a small molecule pharmaceutical. Patiromer was first approved as Veltassa on 2015-10-21. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Veltassa (discontinued: Veltassa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Patiromer sorbitex calcium
Tradename
Company
Number
Date
Products
VELTASSAViforN-205739 RX2015-10-21
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
veltassaNew Drug Application2025-01-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperkalemia—D006947E87.5
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Patiromer Sorbitex Calcium, Veltassa, Vifor Pharma
94924762033-10-08U-1766
99252122033-10-08U-1766
111233632033-10-08U-1766
83378242030-05-29DPU-1766
81478732028-06-20DP
82829132027-05-29DP
82165602027-03-14U-1766
75567992025-02-27U-1766
82878472024-03-30U-1766
84757802024-03-30U-1766
87783242024-03-30U-1766
88891152024-03-30U-1766
104858212024-03-30U-1766
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
— V03AE09: Patiromer calcium
HCPCS
No data
Clinical
Clinical Trials
30 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperkalemiaD006947—E87.5—222—6
Kidney diseasesD007674EFO_0003086N08—1—2—3
Chronic renal insufficiencyD051436—N18—1—1—2
Chronic kidney failureD007676EFO_0003884N18.6———1—1
HypertensionD006973EFO_0000537I10———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePatiromer
INNpatiromer calcium
Description
Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut.
Classification
Small molecule
Drug classpolymers; antihyperlipidemic, thyromimetic derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2107875
ChEBI ID—
PubChem CID—
DrugBankDB09263
UNII ID1FQ2RY5YHH (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 752 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
12,888 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use